Ocular Therapeutix Q2 2026: NDA Submission on Track, Cash Runway into 2028
OCUL sits 34% above its 52-week low of $6.23.
Summary
Ocular Therapeutix posted a $(78.8)M net loss in Q2 2026 with $598.6M in cash, and its AXPAXLI NDA submission for wet AMD is on track for Q4 2026 after positive FDA interactions.
Key Events · Earnings and Guidance · OCUL
-
Q2 2026 Financial Results
The quarter delivered a net loss of $(78.8) million, or $(0.35) per share, on total revenue of $13.5 million. Cash and equivalents reached $598.6 million as of June 30, 2026, funding operations into 2028.
-
AXPAXLI NDA Submission on Track
An NDA submission for AXPAXLI in wet AMD is planned for Q4 2026, supported by SOL-1 Week 52 data, interim SOL-R safety data, and confirmatory evidence. A pre-NDA meeting with the FDA is scheduled for Q3 2026.
-
New Post-Hoc Analysis Shows Treatment Burden Reduction
A post-hoc analysis of the SOL-1 trial estimated up to a 72% reduction in treatment burden over 60 weeks with AXPAXLI compared to a projected on-label aflibercept (2 mg) dosing schedule.
-
SOL-R Trial Amended, Topline Data Delayed to Q1 2028
The SOL-R trial will now include superiority to aflibercept 8 mg at Week 96 as a key secondary endpoint, with topline results expected in Q1 2028. The primary endpoint of non-inferiority at Week 56 remains unchanged.
Analysis · OCUL · Life Sciences
A net loss of $(78.8) million, or $(0.35) per share, marked Ocular Therapeutix's Q2 2026, yet a cash position of $598.6 million extends the runway into 2028. The AXPAXLI NDA submission for wet AMD remains on schedule for Q4 2026, buoyed by a positive Type C meeting with the FDA and a pre-NDA meeting set for Q3 2026. Strengthening the commercial narrative, a new post-hoc analysis of the SOL-1 trial revealed up to a 72% reduction in treatment burden versus on-label aflibercept. Meanwhile, the SOL-R trial is being amended to assess superiority to aflibercept 8 mg, pushing topline results to Q1 2028. These developments solidify the path toward a potential 2027 launch of AXPAXLI, a pivotal value driver.
At the time of this filing, OCUL was trading at $8.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $6.23 to $16.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.